Evidence map›Paper›PMID 36465383›Full record

ReviewFrontiers in oncology2022

Insulin-like growth factor binding protein 5: Diverse roles in cancer.

Jennifer A Waters, Ixchel Urbano, Mikella Robinson, Carrie D House

Open access · goldAbstract readReview
In one paragraph

Review in Frontiers in oncology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 36 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
36citing papers in PubMed, 1 pooled it
5.0field-weighted citation impact, top 4% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

36 citing papers in PubMed, 1 synthesis or guideline pooled it, 39 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Review
  4. Review
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. IGF Pathway Components as Potential Biomarkers in Gastric Cancer.International journal of molecular sciences · 2025
    Article
  14. Article
  15. Review
  16. Effects of Different Salinity Conditions on Regulation ofInternational journal of molecular sciences · 2025
    Article
  17. Article
  18. Article
  19. Single-cell analysis reveals CD34NPJ precision oncology · 2025
    Article
  20. American journal of physiology. Endocrinology and metabolism · 2025
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 2 institutions in 1 country.

Jennifer A WatersBiology Department, San Diego State University, San Diego, CA, United States.
Ixchel UrbanoBiology Department, San Diego State University, San Diego, CA, United States.
Mikella RobinsonBiology Department, San Diego State University, San Diego, CA, United States.
Carrie D HouseBiology Department, San Diego State University, San Diego, CA, United States.
San Diego State University · USUniversity of California, San Diego · US

Funding

The Research Infrastructure Core of SDSU HealthLINK Center for Transdisciplinary Health Disparities ResearchU54MD012397 · NIMHD · SAN DIEGO STATE UNIVERSITY · PI Elva M Arredondo · 2018 to 2026
$39.0M
Building Capacity and Infrastructure for Population Health and Health Disparities Research at San Diego State UniversityS21MD010690 · NIMHD · SAN DIEGO STATE UNIVERSITY · PI AYALA, GUADALUPE X, CASTILLO, JOSE E · 2016 to 2020
$10.0M
NIMHD NIH HHS S21 MD010690NIMHD NIH HHS U54 MD012397
6 · The paper itself

Abstract

Insulin-like growth factor binding proteins (IGFBPs) and the associated signaling components in the insulin-like growth factor (IGF) pathway regulate cell differentiation, proliferation, apoptosis, and adhesion. Of the IGFBPs, insulin-like growth factor binding protein 5 (IGFBP5) is the most evolutionarily conserved with a dynamic range of IGF-dependent and -independent functions, and studies on the actions of IGFBP5 in cancer have been somewhat paradoxical. In cancer, the IGFBPs respond to external stimuli to modulate disease progression and therapeutic responsiveness in a context specific manner. This review discusses the different roles of IGF signaling and IGFBP5 in disease with an emphasis on discoveries within the last twenty years, which underscore a need to clarify the IGF-independent actions of IGFBP5, the impact of its subcellular localization, the differential activities of each of the subdomains, and the response to elements of the tumor microenvironment (TME). Additionally, recent advances addressing the role of IGFBP5 in resistance to cancer therapeutics will be discussed. A better understanding of the contexts in which IGFBP5 functions will facilitate the discovery of new mechanisms of cancer progression that may lead to novel therapeutic opportunities.

Indexed as

cancerextracellular matrix (ECM)insulin-like growth factor binding protein 5 (IGFBP5)insulin-like growth factor (IGF)therapy resistancetumor microenvironment (TME)

Identifiers

PMID36465383
PMCPMC9714447
OpenAlexW4309609190

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.